Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
- PMID: 33859547
- PMCID: PMC8042223
- DOI: 10.3389/fnins.2021.649876
Cerebrospinal Fluid Biomarkers of Myeloid and Glial Cell Activation Are Correlated With Multiple Sclerosis Lesional Inflammatory Activity
Abstract
Multiple sclerosis (MS)-related inflammation can be divided into lesional activity, mediated by immune cells migrating from the periphery to the central nervous system (CNS) and non-lesional activity, mediated by inflammation compartmentalized to CNS tissue. Lesional inflammatory activity, reflected by contrast-enhancing lesions (CELs) on the magnetic resonance imaging (MRI), is effectively inhibited by current disease modifying therapies (DMTs). While, the effect of DMTs on non-lesional inflammatory activity is currently unknown. Reliable and simultaneous measurements of both lesional and non-lesional MS activity is necessary to understand their contribution to CNS tissue destruction in individual patients. We previously demonstrated that CNS compartmentalized inflammation can be measured by combined quantification of cerebrospinal fluid (CSF) immune cells and cell-specific soluble markers. The goal of this study is to develop and validate a CSF-biomarker-based molecular surrogate of MS lesional activity. The training cohort was dichotomized into active (CELs > 1 or clinical relapse) and inactive lesional activity (no CELs or relapse) groups. Matched CSF and serum samples were analyzed for 20 inflammatory and axonal damage biomarkers in a blinded fashion. Only the findings from the training cohort with less than 0.1% probability of false positive (i.e., p < 0.001) were validated in an independent validation cohort. MS patients with lesional activity have elevated IL-12p40, CHI3L1, TNFα, TNFβ, and IL-10, with the first two having the strongest effects and validated statistically-significant association with lesional activity in an independent validation cohort. Marker of axonal damage, neurofilament light (NfL), measured in CSF (cNfL) was also significantly elevated in MS patients with active lesions. NfL measured in serum (sNfL) did not differentiate the two MS subgroups with pre-determined significance, (p = 0.0690) even though cCSF and sNfL correlated (Rho = 0.66, p < 0.0001). Finally, the additive model of IL12p40 and CHI3L1 outperforms any biomarker discretely. IL12p40 and CHI3L1, released predominantly by immune cells of myeloid lineage are reproducibly the best CSF biomarkers of MS lesional activity. The residuals from the IL12p40/CHI3L1-cNfL correlations may identify MS patients with more destructive inflammation or contributing neurodegeneration.
Keywords: axonal damage; cerebrospinal fluid biomarkers; contrast-enhancing lesions; lesional inflammatory activity; multiple sclerosis.
Copyright © 2021 Masvekar, Phillips, Komori, Wu and Bielekova.
Conflict of interest statement
MK contributed to this work as a former employee of NINDS, NIH, and the opinions expressed in this manuscript do not represent her current affiliation – Eli Lilly Japan K.K., Kobe, Japan. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures






Similar articles
-
Enhancing the clinical value of serum neurofilament light chain measurement.JCI Insight. 2022 Aug 8;7(15):e161415. doi: 10.1172/jci.insight.161415. JCI Insight. 2022. PMID: 35737460 Free PMC article. Clinical Trial.
-
Determination of chitinase 3-like 1 in cerebrospinal fluid in multiple sclerosis and other neurological diseases.PLoS One. 2020 May 21;15(5):e0233519. doi: 10.1371/journal.pone.0233519. eCollection 2020. PLoS One. 2020. PMID: 32437412 Free PMC article.
-
Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.Front Neurol. 2019 Sep 23;10:1008. doi: 10.3389/fneur.2019.01008. eCollection 2019. Front Neurol. 2019. PMID: 31608004 Free PMC article.
-
Validity of serum neurofilament light chain as a prognostic biomarker of disease activity in multiple sclerosis.J Neurol. 2023 Apr;270(4):1908-1930. doi: 10.1007/s00415-022-11507-y. Epub 2022 Dec 15. J Neurol. 2023. PMID: 36520240 Review.
-
Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis.Rev Neurosci. 2021 Feb 17;32(6):573-595. doi: 10.1515/revneuro-2020-0145. Print 2021 Aug 26. Rev Neurosci. 2021. PMID: 33594840
Cited by
-
Enhancing the clinical value of serum neurofilament light chain measurement.JCI Insight. 2022 Aug 8;7(15):e161415. doi: 10.1172/jci.insight.161415. JCI Insight. 2022. PMID: 35737460 Free PMC article. Clinical Trial.
-
Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations.Int J Mol Sci. 2022 Mar 21;23(6):3383. doi: 10.3390/ijms23063383. Int J Mol Sci. 2022. PMID: 35328802 Free PMC article. Review.
-
Inflammatory and neurodegenerative serum protein biomarkers increase sensitivity to detect clinical and radiographic disease activity in multiple sclerosis.Nat Commun. 2024 May 20;15(1):4297. doi: 10.1038/s41467-024-48602-9. Nat Commun. 2024. PMID: 38769309 Free PMC article.
-
Proteomics Reveals Age as Major Modifier of Inflammatory CSF Signatures in Multiple Sclerosis.Neurol Neuroimmunol Neuroinflamm. 2025 Jan;12(1):e200322. doi: 10.1212/NXI.0000000000200322. Epub 2024 Nov 13. Neurol Neuroimmunol Neuroinflamm. 2025. PMID: 39536291 Free PMC article.
-
Proteomics reveal biomarkers for diagnosis, disease activity and long-term disability outcomes in multiple sclerosis.Nat Commun. 2023 Oct 30;14(1):6903. doi: 10.1038/s41467-023-42682-9. Nat Commun. 2023. PMID: 37903821 Free PMC article.
References
-
- Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., et al. (2000). Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6 1167–1175. 10.1038/80516 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources